Hillstar Bio has successfully closed a $67 million Series A financing round led by various investors. The funds will be used to advance their lead TRBV9 program and broaden their pipeline in precision immunotherapy.
Hillstar Bio has successfully closed a $67 million Series A financing round led by various investors. The funds will be used to advance their lead TRBV9 program and broaden their pipeline in precision immunotherapy.
03/25/25, 10:36 AM
Location
bostonMoney raised
$67 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Hummingbird Bioscience, Life Arc Ventures, Novo Holdings A/S, Frazier Life Sciences, Droia Ventures
Hillstar Bio, a biotechnology company, announced the successful closing of a $67 million Series A financing round. The funding was led by a syndicate of investors from the U.S., Europe, and Asia, including Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc Ventures, and Hummingbird Bioscience. The proceeds will fund the advancement of the company's lead TRBV9 program and progress their broader pipeline in autoimmune treatments. Hillstar Bio focuses on a precision-driven approach to target pathogenic immune cells while preserving healthy ones.
Company Info
Location
boston, massachusetts, united states
Additional Info
Hillstar Bio is a biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases. Their approach selectively targets and depletes pathogenic immune cells while preserving healthy ones, aiming to provide durable relief and improve patient outcomes. The company's innovative methods leverage tailored discovery techniques, distinguishing them from traditional drug development. They are advancing a pipeline of therapies aimed at specific immune cell subsets for various autoimmune disorders.